Is Candel Therapeutics, Inc. (CADL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.7% / 30% | 28.4% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 3.7% / 33% | 28.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 12.6% / 33% | 96.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.7% / 33% | 28.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 12.6% / 33% | 96.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -64.6% | |
| Return on Assets (ROA) | -25.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$38M |
| Free Cash Flow | -$39M |
| Total Debt | $49M |
| Debt-to-Equity | 94.4 |
| Current Ratio | 13.5 |
| Total Assets | $125M |
Price & Trading
| Last Close | $4.88 |
| 50-Day MA | $5.42 |
| 200-Day MA | $5.51 |
| Avg Volume | 1.1M |
| Beta | -0.9 |
|
52-Week Range
$4.25
| |
About Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Candel Therapeutics, Inc. (CADL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Candel Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Candel Therapeutics, Inc.'s debt ratio?
Candel Therapeutics, Inc.'s debt ratio is 3.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.6%.
What are Candel Therapeutics, Inc.'s key financial metrics?
Candel Therapeutics, Inc. has a market capitalization of $352M. Return on equity stands at -64.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.